Key result
Fabry disease is linked to ~37% higher plasma S1P levels and adverse cardiovascular remodeling.
Why the study?
Is sphingosine-1 phosphate associated with cardiovascular remodeling in patients with Fabry disease?
Case-Control (n=34)
Is sphingosine-1 phosphate associated with cardiovascular remodeling in patients with Fabry disease?
Answers are grounded in this paper and cite their sources.
Sphingosine-1 phosphate is elevated in Fabry disease and correlates with cardiovascular remodeling, suggesting a potential pathogenic role and therapeutic target.
AIMS: A hallmark of Fabry disease is the concomitant development of left-ventricular hypertrophy and arterial intima-media thickening, the pathogenesis of which is thought to be related to the presence of a plasmatic circulating growth-promoting factor. We therefore characterized the plasma of patients with Fabry disease in order to identify this factor. METHODS AND RESULTS: Using a classical biochemical strategy, we isolated and identified sphingosine-1 phosphate (S1P) as a proliferative factor present in the plasma of patients with Fabry disease. Plasma S1P levels were significantly higher in 17 patients with Fabry disease compared with 17 healthy controls (225 +/- 40 vs. 164 +/- 17 ng/mL; P = 0.005). There was a positive correlation between plasma S1P levels and both common carotid artery intima-media thickness and left-ventricular mass index (r(2) = 0.47; P = 0.006 and r(2) = 0.53; P = 0.0007, respectively). In an experimental model, mice treated with S1P developed cardiovascular remodelling similar to that observed in patients with Fabry disease. CONCLUSION: Sphingosine-1 phosphate participates in cardiovascular remodelling in Fabry disease. Our findings have implications for the treatment of cardiovascular involvement in Fabry disease.
No takes yet. Share an insight, caveat, or question.
Brakch et al. (2009) conducted a case-control in Fabry disease (n=34). Fabry disease vs. Healthy controls was evaluated on Plasma sphingosine-1 phosphate (S1P) levels (p=0.005). Patients with Fabry disease had higher plasma sphingosine-1 phosphate levels than healthy controls, correlating with cardiovascular remodeling.
Synapse has enriched 10 related papers. Consider them for comparative context: